Number of cases and crude incidence rates (IR) per 100 000 for lymphoid malignancies by sex and morphologic type diagnosed in 2000-2002 and archived in 44 European CRs
| HAEMACARE groupings . | ICD-O-3 code . | ICD-O-3 description . | No. of cases . | All . | Males . | Females . | |||
|---|---|---|---|---|---|---|---|---|---|
| IR . | 95% CI . | IR . | 95% CI . | IR . | 95% CI . | ||||
| HL | 5571 | 2.49 | (2.42-2.55) | 2.81 | (2.71-2.91) | 2.18 | (2.09-2.26) | ||
| HL, nodular lymphocyte predominance | 9659 | HL, nodular lymphocyte predominance | 195 | 0.09 | (0.08-0.10) | 0.12 | (0.10-0.15) | 0.05 | (0.04-0.07) |
| Classic HL | 5376 | 2.40 | (2.34-2.47) | 2.69 | (2.59-2.79) | 2.12 | (2.04-2.21) | ||
| 9650 | HL, NOS | 996 | 0.44 | (0.42-0.47) | 0.52 | (0.48-0.57) | 0.37 | (0.34-0.41) | |
| 9661 | Hodgkin granuloma (obsolete) | ||||||||
| 9662 | Hodgkin sarcoma (obsolete) | ||||||||
| 9651 | HL, lymphocyte rich | 217 | 0.10 | (0.08-0.11) | 0.13 | (0.11-0.15) | 0.07 | (0.05-0.08) | |
| 9663 | HL, nodular sclerosis, NOS | 3165 | 1.41 | (1.36-1.46) | 1.45 | (1.38-1.53) | 1.37 | (1.31-1.44) | |
| 9664 | HL, nodular sclerosis cellular phase | ||||||||
| 9665 | HL, nodular sclerosis grade 1 | ||||||||
| 9667 | HL, nodular sclerosis grade 2 | ||||||||
| 9652 | HL, mixed cellularity, NOS | 909 | 0.41 | (0.38-0.43) | 0.53 | (0.49-0.58) | 0.28 | (0.25-0.32) | |
| 9653 | HL, lymphocyte depletion, NOS | 89 | 0.04 | (0.03-0.05) | 0.05 | (0.04-0.07) | 0.03 | (0.02-0.04) | |
| 9654 | HL, lymphocyte depletion, diffuse fibrosis | ||||||||
| 9655 | HL, lymphocyte depletion, reticular | ||||||||
| Mature B-cell neoplasms | 42 855 | 19.14 | (18.96-19.32) | 21.30 | (21.03-21.57) | 17.07 | (16.83-17.31) | ||
| SBLL/CLL | 9670 | Malignant lymphoma, small B-cell lymphocytic, NOS | 11 019 | 4.92 | (4.83-5.01) | 5.87 | (5.73-6.02) | 4.01 | (3.90-4.13) |
| 9823 | B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma | ||||||||
| Immunoproliferative diseases | 9671 | Malignant lymphoma, lymphoplasmacytic | 1859 | 0.83 | (0.79-0.87) | 1.00 | (0.94-1.06) | 0.67 | (0.63-0.72) |
| 9760 | Immunoproliferative disease, NOS | ||||||||
| 9761 | Waldenström macroglobulinemia | ||||||||
| 9762 | Heavy chain disease, NOS | ||||||||
| Mantle cell/centrocytic lymphoma | 9673 | Mantle cell lymphoma | 1012 | 0.45 | (0.42-0.48) | 0.64 | (0.60-0.69) | 0.27 | (0.24-0.30) |
| Follicular B-cell lymphoma | 9690 | Follicular lymphoma, NOS | 4881 | 2.18 | (2.12-2.24) | 2.10 | (2.01-2.19) | 2.26 | (2.17-2.35) |
| 9691 | Follicular lymphoma, grade 2 | ||||||||
| 9695 | Follicular lymphoma, grade 1 | ||||||||
| 9698 | Follicular lymphoma, grade 3 | ||||||||
| Diffuse B-cell lymphoma | 9675 | Malignant lymphoma, mixed small and large cell, diffuse (obsolete) | 8538 | 3.81 | (3.73-3.89) | 4.06 | (3.95-4.19) | 3.57 | (3.46-3.68) |
| 9678 | Primary effusion lymphoma | ||||||||
| 9679 | Mediastinal large B-cell lymphoma | ||||||||
| 9680 | Malignant lymphoma, large B-cell, diffuse, NOS | ||||||||
| 9684 | Malignant lymphoma, large B-cell, diffuse, immunoblastic, NOS | ||||||||
| Burkitt lymphoma/leukemia | 9687 | Burkitt lymphoma, NOS | 488 | 0.22 | (0.20-0.24) | 0.31 | (0.27-0.34) | 0.13 | (0.11-0.16) |
| 9826 | Burkitt cell leukemia | ||||||||
| Marginal zone lymphoma | 9689 | Splenic marginal zone B-cell lymphoma | 950 | 0.42 | (0.40-0.45) | 0.40 | (0.36-0.44) | 0.45 | (0.41-0.49) |
| 9699 | Marginal zone B-cell lymphoma, NOS/mucosa-associated lymphoid tissue lymphoma | ||||||||
| 9764 | Immunoproliferative small intestinal disease (Mediterranean lymphoma) | ||||||||
| Mature B-cell leukemia | 9833 | Prolymphocytic leukemia, B-cell type | 652 | 0.29 | (0.27-0.31) | 0.46 | (0.42-0.50) | 0.13 | (0.11-0.15) |
| 9940 | Hairy cell leukemia | ||||||||
| Plasma cell neoplasms | 13 456 | 6.01 | (5.91-6.11) | 6.46 | (6.31-6.61) | 5.58 | (5.44-5.72) | ||
| 9732 | Multiple myeloma | 12 192 | 5.44 | (5.35-5.54) | 5.85 | (5.70-5.99) | 5.06 | (4.93-5.19) | |
| 9733 | Plasma cell leukemia | 92 | 0.04 | (0.03-0.05) | 0.04 | (0.03-0.05) | 0.05 | (0.03-0.06) | |
| 9731 | Plasmacytoma, NOS | 1172 | 0.52 | (0.49-0.55) | 0.58 | (0.53-0.62) | 0.47 | (0.43-0.51) | |
| 9734 | Plasmacytoma, extramedullary | ||||||||
| Mature T-cell and NK-cell neoplasms | 2527 | 1.13 | (1.08-1.17) | 1.41 | (1.34-1.48) | 0.86 | (0.81-0.92) | ||
| Cutaneous T-cell lymphoma | 9700 | Mycosis fungoides | 1208 | 0.54 | (0.51-0.57) | 0.68 | (0.64-0.73) | 0.40 | (0.37-0.44) |
| 9701 | Sézary syndrome | ||||||||
| 9708 | Subcutaneous T panniculitis-like T-cell lymphoma | ||||||||
| 9709 | Cutaneous T-cell lymphoma, NOS | ||||||||
| 9718 | Primary cutaneous CD30+ T-cell lymphoproliferative disorder | ||||||||
| Other T-cell lymphomas | 9702 | Mature T-cell lymphoma, NOS | 1319 | 0.59 | (0.56-0.62) | 0.72 | (0.67-0.78) | 0.46 | (0.42-0.50) |
| 9705 | Angioimmunoblastic T-cell lymphoma | ||||||||
| 9714 | Anaplastic large cell lymphoma, T-cell and null cell type | ||||||||
| 9716 | Hepatosplenic γδ cell lymphoma | ||||||||
| 9717 | Intestinal T-cell lymphoma | ||||||||
| 9948 | Aggressive NK-cell leukemia | ||||||||
| 9719 | NK/T-cell lymphoma, nasal and nasal-type | ||||||||
| 9827 | Adult T-cell leukemia/lymphoma (HTLV-1 positive) | ||||||||
| 9831 | T-cell large granular lymphocytic leukemia | ||||||||
| 9834 | Prolymphocytic leukemia, T-cell type | ||||||||
| Lymphoblastic lymphoma/acute (precursor cell) lymphatic leukemia | 2863 | 1.28 | (1.23-1.33) | 1.44 | (1.37-1.51) | 1.12 | (1.06-1.19) | ||
| B-cell | 9728 | Precursor B-cell lymphoblastic lymphoma | 190 | 0.08 | (0.07-0.10) | 0.09 | (0.07-0.11) | 0.08 | (0.06-0.10) |
| 9836 | Precursor B-cell lymphoblastic leukemia | ||||||||
| T-cell | 9729 | Precursor T-cell lymphoblastic lymphoma | 64 | 0.03 | (0.02-0.04) | 0.04 | (0.03-0.06) | 0.01 | (0.01-0.02) |
| 9837 | Precursor T-cell lymphoblastic leukemia | ||||||||
| NOS | 9727 | Precursor cell lymphoblastic lymphoma, NOS | 2609 | 1.17 | (1.12-1.21) | 1.31 | (1.24-1.38) | 1.03 | (0.97-1.09) |
| 9835 | Precursor cell lymphoblastic leukemia, NOS | ||||||||
| Unknown lymphoid neoplasms | 12 547 | 5.60 | (5.51-5.70) | 5.87 | (5.72-6.01) | 5.35 | (5.22-5.49) | ||
| Lymphoma, NOS | 9590 | Malignant lymphoma, NOS | 4803 | 2.14 | (2.08-2.21) | 2.21 | (2.12-2.30) | 2.09 | (2.00-2.17) |
| NHL, NOS | 9591 | Malignant lymphoma, NHL, NOS | 7450 | 3.33 | (3.25-3.40) | 3.51 | (3.40-3.62) | 3.15 | (3.05-3.25) |
| Lymphatic leukemia, NOS | 9820 | Lymphoid leukemia, NOS | 294 | 0.13 | (0.12-0.15) | 0.15 | (0.13-0.17) | 0.12 | (0.10-0.14) |
| 9832 | Prolymphocytic leukemia, NOS | ||||||||
| All lymphoid malignancies* | 66 371 | 29.64 | (29.41-29.86) | 32.83 | (32.49-33.17) | 26.59 | (26.29-26.89) | ||
| HAEMACARE groupings . | ICD-O-3 code . | ICD-O-3 description . | No. of cases . | All . | Males . | Females . | |||
|---|---|---|---|---|---|---|---|---|---|
| IR . | 95% CI . | IR . | 95% CI . | IR . | 95% CI . | ||||
| HL | 5571 | 2.49 | (2.42-2.55) | 2.81 | (2.71-2.91) | 2.18 | (2.09-2.26) | ||
| HL, nodular lymphocyte predominance | 9659 | HL, nodular lymphocyte predominance | 195 | 0.09 | (0.08-0.10) | 0.12 | (0.10-0.15) | 0.05 | (0.04-0.07) |
| Classic HL | 5376 | 2.40 | (2.34-2.47) | 2.69 | (2.59-2.79) | 2.12 | (2.04-2.21) | ||
| 9650 | HL, NOS | 996 | 0.44 | (0.42-0.47) | 0.52 | (0.48-0.57) | 0.37 | (0.34-0.41) | |
| 9661 | Hodgkin granuloma (obsolete) | ||||||||
| 9662 | Hodgkin sarcoma (obsolete) | ||||||||
| 9651 | HL, lymphocyte rich | 217 | 0.10 | (0.08-0.11) | 0.13 | (0.11-0.15) | 0.07 | (0.05-0.08) | |
| 9663 | HL, nodular sclerosis, NOS | 3165 | 1.41 | (1.36-1.46) | 1.45 | (1.38-1.53) | 1.37 | (1.31-1.44) | |
| 9664 | HL, nodular sclerosis cellular phase | ||||||||
| 9665 | HL, nodular sclerosis grade 1 | ||||||||
| 9667 | HL, nodular sclerosis grade 2 | ||||||||
| 9652 | HL, mixed cellularity, NOS | 909 | 0.41 | (0.38-0.43) | 0.53 | (0.49-0.58) | 0.28 | (0.25-0.32) | |
| 9653 | HL, lymphocyte depletion, NOS | 89 | 0.04 | (0.03-0.05) | 0.05 | (0.04-0.07) | 0.03 | (0.02-0.04) | |
| 9654 | HL, lymphocyte depletion, diffuse fibrosis | ||||||||
| 9655 | HL, lymphocyte depletion, reticular | ||||||||
| Mature B-cell neoplasms | 42 855 | 19.14 | (18.96-19.32) | 21.30 | (21.03-21.57) | 17.07 | (16.83-17.31) | ||
| SBLL/CLL | 9670 | Malignant lymphoma, small B-cell lymphocytic, NOS | 11 019 | 4.92 | (4.83-5.01) | 5.87 | (5.73-6.02) | 4.01 | (3.90-4.13) |
| 9823 | B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma | ||||||||
| Immunoproliferative diseases | 9671 | Malignant lymphoma, lymphoplasmacytic | 1859 | 0.83 | (0.79-0.87) | 1.00 | (0.94-1.06) | 0.67 | (0.63-0.72) |
| 9760 | Immunoproliferative disease, NOS | ||||||||
| 9761 | Waldenström macroglobulinemia | ||||||||
| 9762 | Heavy chain disease, NOS | ||||||||
| Mantle cell/centrocytic lymphoma | 9673 | Mantle cell lymphoma | 1012 | 0.45 | (0.42-0.48) | 0.64 | (0.60-0.69) | 0.27 | (0.24-0.30) |
| Follicular B-cell lymphoma | 9690 | Follicular lymphoma, NOS | 4881 | 2.18 | (2.12-2.24) | 2.10 | (2.01-2.19) | 2.26 | (2.17-2.35) |
| 9691 | Follicular lymphoma, grade 2 | ||||||||
| 9695 | Follicular lymphoma, grade 1 | ||||||||
| 9698 | Follicular lymphoma, grade 3 | ||||||||
| Diffuse B-cell lymphoma | 9675 | Malignant lymphoma, mixed small and large cell, diffuse (obsolete) | 8538 | 3.81 | (3.73-3.89) | 4.06 | (3.95-4.19) | 3.57 | (3.46-3.68) |
| 9678 | Primary effusion lymphoma | ||||||||
| 9679 | Mediastinal large B-cell lymphoma | ||||||||
| 9680 | Malignant lymphoma, large B-cell, diffuse, NOS | ||||||||
| 9684 | Malignant lymphoma, large B-cell, diffuse, immunoblastic, NOS | ||||||||
| Burkitt lymphoma/leukemia | 9687 | Burkitt lymphoma, NOS | 488 | 0.22 | (0.20-0.24) | 0.31 | (0.27-0.34) | 0.13 | (0.11-0.16) |
| 9826 | Burkitt cell leukemia | ||||||||
| Marginal zone lymphoma | 9689 | Splenic marginal zone B-cell lymphoma | 950 | 0.42 | (0.40-0.45) | 0.40 | (0.36-0.44) | 0.45 | (0.41-0.49) |
| 9699 | Marginal zone B-cell lymphoma, NOS/mucosa-associated lymphoid tissue lymphoma | ||||||||
| 9764 | Immunoproliferative small intestinal disease (Mediterranean lymphoma) | ||||||||
| Mature B-cell leukemia | 9833 | Prolymphocytic leukemia, B-cell type | 652 | 0.29 | (0.27-0.31) | 0.46 | (0.42-0.50) | 0.13 | (0.11-0.15) |
| 9940 | Hairy cell leukemia | ||||||||
| Plasma cell neoplasms | 13 456 | 6.01 | (5.91-6.11) | 6.46 | (6.31-6.61) | 5.58 | (5.44-5.72) | ||
| 9732 | Multiple myeloma | 12 192 | 5.44 | (5.35-5.54) | 5.85 | (5.70-5.99) | 5.06 | (4.93-5.19) | |
| 9733 | Plasma cell leukemia | 92 | 0.04 | (0.03-0.05) | 0.04 | (0.03-0.05) | 0.05 | (0.03-0.06) | |
| 9731 | Plasmacytoma, NOS | 1172 | 0.52 | (0.49-0.55) | 0.58 | (0.53-0.62) | 0.47 | (0.43-0.51) | |
| 9734 | Plasmacytoma, extramedullary | ||||||||
| Mature T-cell and NK-cell neoplasms | 2527 | 1.13 | (1.08-1.17) | 1.41 | (1.34-1.48) | 0.86 | (0.81-0.92) | ||
| Cutaneous T-cell lymphoma | 9700 | Mycosis fungoides | 1208 | 0.54 | (0.51-0.57) | 0.68 | (0.64-0.73) | 0.40 | (0.37-0.44) |
| 9701 | Sézary syndrome | ||||||||
| 9708 | Subcutaneous T panniculitis-like T-cell lymphoma | ||||||||
| 9709 | Cutaneous T-cell lymphoma, NOS | ||||||||
| 9718 | Primary cutaneous CD30+ T-cell lymphoproliferative disorder | ||||||||
| Other T-cell lymphomas | 9702 | Mature T-cell lymphoma, NOS | 1319 | 0.59 | (0.56-0.62) | 0.72 | (0.67-0.78) | 0.46 | (0.42-0.50) |
| 9705 | Angioimmunoblastic T-cell lymphoma | ||||||||
| 9714 | Anaplastic large cell lymphoma, T-cell and null cell type | ||||||||
| 9716 | Hepatosplenic γδ cell lymphoma | ||||||||
| 9717 | Intestinal T-cell lymphoma | ||||||||
| 9948 | Aggressive NK-cell leukemia | ||||||||
| 9719 | NK/T-cell lymphoma, nasal and nasal-type | ||||||||
| 9827 | Adult T-cell leukemia/lymphoma (HTLV-1 positive) | ||||||||
| 9831 | T-cell large granular lymphocytic leukemia | ||||||||
| 9834 | Prolymphocytic leukemia, T-cell type | ||||||||
| Lymphoblastic lymphoma/acute (precursor cell) lymphatic leukemia | 2863 | 1.28 | (1.23-1.33) | 1.44 | (1.37-1.51) | 1.12 | (1.06-1.19) | ||
| B-cell | 9728 | Precursor B-cell lymphoblastic lymphoma | 190 | 0.08 | (0.07-0.10) | 0.09 | (0.07-0.11) | 0.08 | (0.06-0.10) |
| 9836 | Precursor B-cell lymphoblastic leukemia | ||||||||
| T-cell | 9729 | Precursor T-cell lymphoblastic lymphoma | 64 | 0.03 | (0.02-0.04) | 0.04 | (0.03-0.06) | 0.01 | (0.01-0.02) |
| 9837 | Precursor T-cell lymphoblastic leukemia | ||||||||
| NOS | 9727 | Precursor cell lymphoblastic lymphoma, NOS | 2609 | 1.17 | (1.12-1.21) | 1.31 | (1.24-1.38) | 1.03 | (0.97-1.09) |
| 9835 | Precursor cell lymphoblastic leukemia, NOS | ||||||||
| Unknown lymphoid neoplasms | 12 547 | 5.60 | (5.51-5.70) | 5.87 | (5.72-6.01) | 5.35 | (5.22-5.49) | ||
| Lymphoma, NOS | 9590 | Malignant lymphoma, NOS | 4803 | 2.14 | (2.08-2.21) | 2.21 | (2.12-2.30) | 2.09 | (2.00-2.17) |
| NHL, NOS | 9591 | Malignant lymphoma, NHL, NOS | 7450 | 3.33 | (3.25-3.40) | 3.51 | (3.40-3.62) | 3.15 | (3.05-3.25) |
| Lymphatic leukemia, NOS | 9820 | Lymphoid leukemia, NOS | 294 | 0.13 | (0.12-0.15) | 0.15 | (0.13-0.17) | 0.12 | (0.10-0.14) |
| 9832 | Prolymphocytic leukemia, NOS | ||||||||
| All lymphoid malignancies* | 66 371 | 29.64 | (29.41-29.86) | 32.83 | (32.49-33.17) | 26.59 | (26.29-26.89) | ||
Eight cases of composite HL and NHL (ICD-O-3 code 9596) not shown in Table 2 have been included in the totals.